The stock of Roivant Sciences Ltd. (NASDAQ:ROIV) decreased by -$0.04 on Tuesday to finish at $11.25, down -0.35 percent. The last five days have seen an average of 2,462,880 shares of common stock traded. 13 times new highs were reached in the current year, with a gain of $3.26. The average number of shares traded over the last 20 days was 3,355,325, while the average volume over the last 50 days totaled 5,407,836.
ROIV stock dropped -6.09% since last month. On 08/18/23, the company’s shares reached a one-month low of $10.24. The stock touched a high of $12.01 on 07/18/23, after rallying from a low of $2.87 in 52 weeks. The price of ROIV stock has risen by 40.80% or $3.26 this year, reaching a new high 13 times. Still, the stock price is down -6.29% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
ROIV stock investors should be aware that Roivant Sciences Ltd. (ROIV) stock had its last reported insider trading activity 16 days ago on Aug 14. On Aug 14, Chief Operating Officer Venker Eric sold 59,811 shares at $11.89 each. This transaction resulted in the insider making $711,153. On Aug 03, Venker Eric sold 44,629 shares at a price of US$11.93. After the transaction, the insider now owns 627,918 shares. Chief Accounting Officer Kumar Rakhi had earlier sold 3,681 shares on Aug 03 for $12.00 a share. The transaction was completed for $44,172.
Valuation Metrics
Beta for the stock is 1.29. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 110.16, the price-to-book (PB) ratio of 9.38.
Financial Health
For the recent quarter, Roivant Sciences Ltd.’s quick ratio was 6.40, while its current ratio was 6.40, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the recent quarter is 0.42, and the total debt to equity ratio is 0.47. As far as profitability goes, gross margin for the trailing twelve months is 80.10% percent. Based on annual data, it had gross profit of $48.15 million and revenue of $61.28 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. There was a -72.90% return on investment (ROI) in the past year.
Earnings Surprise
A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $21.62 million, while revenues rose by 80.02% to $27.38 million. EBITDA was -$270.57 million for the quarter. At the end of Roivant Sciences Ltd.’s most recent quarter, its liabilities totaled 802.51 million, while its total debt was $492.64 million. Equity owned by shareholders amounts to $771.74 million.
Technical Picture
Here’s a quick look at Roivant Sciences Ltd.’s (ROIV) price momentum from a technical perspective. As of 29 August, the RSI 9-day stood at 51.19%, suggesting the stock is Neutral, with a 48.16% historical volatility rate.
The stochastic %K and %D were 57.36% and 58.27% respectively, while the average true range (ATR) was 0.48. Based on the 14-day stochastic reading of 58.72%, the RSI (14) reading is 51.57%. On the 9-day MACD Oscillator, the stock is at 0.12, and the 14-day reading is at 0.06.
Analyst Ratings
In its analyst report released on June 08, 2023, BofA Securities began covering Roivant Sciences Ltd. (NASDAQ: ROIV). The stock was rated as a Neutral by the brokerage firm.
